论文部分内容阅读
目的 :研究恶性造血细胞表面Flt3受体的表达 ,TNFα和地塞米松 (DXM )对Flt3受体表达的作用及重组人Flt3配体 (rhFL)对恶性造血细胞增殖的影响。方法 :用流式细胞仪测定 18株体外培养的恶性造血细胞株细胞表面Flt3受体 ,用MTT法测定rhFL对恶性造血细胞增殖的影响。结果 :5株细胞表面存在Flt3受体。B淋巴瘤细胞株Raji、Daudi及多发性骨髓瘤细胞株 82 6 6表达高水平Flt3受体 ;髓系白血病细胞株HL 6 0和多发性骨髓瘤细胞株XG 6表达低水平的Flt3受体。用 10 -6mol/LDXM培养 2 4h后 ,上述细胞Flt3受体表达降低 ;用2 0ng/mlTNFα培养 2 4h后 ,Raji和 82 6 6细胞Flt3受体表达降低 ,HL 6 0和XG 6细胞Flt3受体表达增高 ,Daudi细胞Flt3受体表达不受影响。rhFL在 10～ 10 0ng/ml浓度时 ,刺激Raji和HL 6 0细胞的增殖 (P <0 0 5 ) ,但对绝大多数的恶性造血细胞体外无刺激作用。结论 :多数恶性造血细胞不表达Flt3受体 ;rhFL也不引起此类细胞的增殖。地塞米松降低Flt3受体的表达 ,有可能用于防止或降低FL对部分恶性造血细胞的刺激作用 ,使FL的应用更为安全。
Objective: To study the expression of Flt3 receptor on the surface of malignant hematopoietic cells, the effect of TNFα and dexamethasone (DXM) on the expression of Flt3 receptor and the effect of recombinant human Flt3 ligand (rhFL) on the proliferation of malignant hematopoietic cells. Methods: Flt3 receptors on the surface of 18 malignant hematopoietic cell lines in vitro were determined by flow cytometry. The effect of rhFL on the proliferation of malignant hematopoietic cells was measured by MTT assay. Results: Flt3 receptors were present on the surface of 5 cells. The B lymphoma cell lines Raji, Daudi and the multiple myeloma cell line 8266 express high-level Flt3 receptors; the myeloid leukemia cell line HL 60 and the multiple myeloma cell line XG 6 express low levels of the Flt3 receptor. After cultured for 24 hours with 10 -6 mol/L dxm, the expression of Flt3 receptor was decreased. After 24 h culture with 20 ng/ml TNFα, the expression of Flt3 receptor in Raji and 8266 cells was decreased, and HL 60 and XG 6 cell Flt3 were affected. Increased body expression did not affect Flt3 receptor expression in Daudi cells. RhFL stimulated proliferation of Raji and HL 60 cells (P < 0.05) at a concentration of 10 to 10 0ng/ml, but it did not stimulate most malignant hematopoietic cells in vitro. Conclusion: Most malignant hematopoietic cells do not express Flt3 receptor; rhFL does not cause proliferation of such cells. Dexamethasone reduces the expression of Flt3 receptor and may be used to prevent or reduce the stimulatory effect of FL on some malignant hematopoietic cells, making the application of FL more secure.